One-Year Follow-up of Young People with ME/CFS Following Infectious Mononucleosis by Epstein-Barr Virus

- 1 Rafael Pricoco¹, Paulina Meidel¹, Tim Hofberger¹, Hannah Zietemann¹, Yvonne Mueller¹,
- 2 Katharina Wiehler¹, Kaja Michel¹, Johannes Paulick¹, Ariane Leone¹, Matthias Haegele¹,

3 Sandra Mayer-Huber¹, Katrin Gerrer¹, Kirstin Mittelstrass¹, Carmen Scheibenbogen², Herbert

4 **Renz-Polster³**, Lorenz Mihatsch^{1,†,*}, Uta Behrends^{1,4,†}

- ⁵ ¹MRI Chronic Fatigue Center for Young People (MCFC), Children's Hospital, TUM School of
- 6 Medicine, Technical University of Munich and Munich Municipal Hospital Schwabing, Munich,

7 Germany

- 8 ² Institut für Med. Immunologie, Immundefektambulanz, Charité Universitätsmedizin Berlin;
- 9 Campus Virchow-Klinikum (CVK), Berlin, Germany
- ³ Mannheim Institute of Public Health, Social and Preventive Medicine, University Medicine
- 11 Mannheim, Heidelberg, Germany
- ⁴German Center of Infection Research (DZIF), Germany
- 13 [†]These authors contributed equally to this work and share last authorship

- 15 ***Correspondence:**
- 16 Lorenz Mihatsch
- 17 l.mihatsch@tum.de
- 18 Keywords: Myalgic encephalomyelitis, chronic fatigue syndrome, infectious mononucleosis,
- 19 Epstein-Barr virus, EBV, adolescents, ME/CFS, follow-up
- 20
- 21
- 22
- 23

Contribution to the Field

Few follow-up studies on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in young people exist, and none have included young adults. This study presents the first one-year follow-up of a cohort of adolescent and young adult patients with ME/CFS following infectious mononucleosis by the Epstein-Barr virus (EBV-IM) in Germany. Our findings shed light on the debilitating nature of ME/CFS in young people and provide valuable insights into the natural course of the disease, lasting longer than one year in many patients. Additionally, the study reveals that young adults with ME/CFS experience more severe symptoms and have poorer physical and mental functioning compared to adolescents. Adolescents have a better prognosis, with improvements in physical functioning, and health-related quality of life. Overall, this study provides valuable clinical data on ME/CFS following EBV-IM in young people, emphasizing the urgent need for effective biomarkers and therapeutic options.

55 Abstract

56 **Background:** Infectious mononucleosis, caused by the Epstein-Barr Virus (EBV-IM), has been 57 linked to the development of myalgic encephalomyelitis/chronic fatigue-syndrome (ME/CFS) in 58 children, adolescents, and young adults. Our study presents the first cohort of young individuals in 59 Germany who were diagnosed with ME/CFS following EBV-IM.

Methods: We conducted a one-year follow-up of 25 young people diagnosed with ME/CFS at our specialized tertiary outpatient service by clinical criteria requiring post-exertional malaise and with documented EBV-IM as the triggering event. Demographic information, laboratory findings, frequency and severity of symptoms, physical functioning, and health-related quality of life (HRQoL) were assessed at first visit as well as 6 and 12 months later at follow-up visits.

65 **Results:** The physical functioning and HRQoL of the cohort were significantly impaired, with 66 young adults displaying more severe symptoms, as well as worsening of fatigue, physical and mental 67 functioning, and HRQoL throughout the study, compared to adolescents. After one year, we found 68 that 6/12 (54%) adolescents no longer met the diagnostic criteria for ME/CFS, indicating partial 69 remission, while all young adults continued to fulfill the Canadian consensus criteria. Improvement 70 in children was evident in physical functioning, symptom frequency and severity, and HRQoL, while 71 young adults had little improvement. EBV serology and EBV DNA load did not correlate with 72 distinct clinical features of ME/CFS, and clinical chemistry showed no evidence of inflammation. 73 Remarkably, the median time from symptom onset to ME/CFS diagnosis was 13.8 (IQR: 9.1–34.9) 74 months.

Conclusions: ME/CFS following EBV-IM in young people is a severely debilitating disease with diagnoses protracted longer than one year in many patients and only limited responses to conventional symptom-oriented medical care. Although younger children may have a better prognosis, their condition can fluctuate and significantly impact their HRQoL. Our data emphasize that biomarkers and effective therapeutic options are also urgently needed for this very young age group to better manage their medical condition and pave the way to recovery.

81 **1 Introduction**

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and debilitating multi-system disease characterized by fatigue and post-exertional malaise (PEM) together with additional symptoms, including unrefreshing sleep, cognitive impairment, orthostatic intolerance, and/or chronic pain. It has a profound impact on all aspects of daily life. Up to 25% of patients are severely affected and bound to home or bed [1, 2]. ME/CFS has been identified as an important cause for long-lasting school absence [3-8] and results in a significant reduction of health-related quality of life (HRQoL) [7, 9-11].

Although ME/CFS is not rare, it is still not well recognized by doctors, teachers, and the general population. Pre-pandemic global prevalence estimates for ME/CFS were 0.3–0.5%, with two age peaks at onset of 11–19 and 30–39 years [12]. The prevalence reported for children and adolescents ranged from 0.1% to 1.9%, depending on the case definition, geographical region, and screening method. A study from the US indicated that up to 95% of children with ME/CFS may remain undiagnosed [13]. The post-pubertal female-to-male ratio is 3–4:1 [13, 14], thus adolescent girls are predominant amongst ME/CFS patients in pediatrics.

96 Infectious diseases are the most frequent triggers of ME/CFS, accounting for 23-90% pediatric 97 cases [4, 15-17]. Of a large pediatric cohort from Australia 80% of patients recalled an initial 98 infection, and 40% a triggering infectious mononucleosis by Epstein-Barr virus (EBV-IM) [7]. 99 ME/CFS was reported in 13%, 7%, and 4% of 301 adolescents in the US at 6, 12, and 24 months 100 after the onset of EBV-IM [18, 19], respectively, and in 23% of 238 college students at 3-6 months 101 after EBV-IM. 8% of these college students were severely affected [20]. While EBV was recognized 102 as the most prominent viral trigger of ME/CFS until 2019 [7, 19-31], it became outranked by severe 103 acute respiratory coronavirus type 2 (SARS-CoV2), which was estimated to cause at least a doubling 104 of ME/CFS cases worldwide and in Germany [32-34].

The pathomechanisms of ME/CFS and PEM are not yet fully understood. Genetic polymorphisms might contribute to pathogenic immune dysregulation after infections [35]. Evidence is increasing that immunological and vascular changes might result in hypoperfusion of muscles and brain [36]. Microbiome dysbiosis, defects in energy metabolism, dysregulated hormones, and vagus nerve dysfunction have been discussed [21, 37-39]. A causative role of herpes virus reactivation was evaluated but has not been proven yet [40-45]. However, we recently reported, that EBV might as well trigger pathogenic autoimmunity by molecular mimicry [46].

Several risk factors have been suggested for ME/CFS after EBV-IM, including disease severity and days-in-bed during the acute phase, initial pain and autonomic symptoms, lower mental health scores, higher scores for anxiety, depression, and perceived stress, female gender, as well as distinct laboratory findings (e.g. elevated CRP and cytokine levels). However, different case definitions have been used and findings were inconsistent [20, 28-30, 47]. Jason and colleagues found that baseline anxiety, stress, depression, or coping skills did not predict the development of ME/CFS after EBV-IM, while preceding symptoms of the ME/CFS spectrum before EBV-IM increased the risk [20].

120 ME/CFS is diagnosed according to clinical criteria and after exclusion of other diseases that might 121 explain the symptoms [48]. In adults the systemic exertion intolerance disease (SEID)/Institute of 122 Medicine (IOM) criteria [49] are recommended for screening and the Canadian Consensus Criteria 123 (CCC) [50] for diagnosis and research. For children and adolescents the CCC were adapted in a 124 "pediatric case definition" (here abbreviated as PCD-J) by Jason and colleagues [51] and modified in 125 a "clinical diagnostic worksheet" (here abbreviated as CDW-R) developed by Rowe and colleagues 126 who thereby referred to less typical pediatric cases [6]. All four scores require PEM as an essential 127 criterion. The interdisciplinary diagnostic workup addresses not only differential diagnoses but also 128 possible comorbidities such as autoimmune thyroiditis, orthostatic intolerance, or hypermobile Ehlers 129 Danlos (hEDS) syndrome, and includes a psychological evaluation. A 10-minute standing test 130 (NASA lean test) or tilt table test is recommended to diagnose postural orthostatic tachycardia 131 syndrome (PoTS) [6, 48] which itself is often triggered by infections.

As of now, no specific treatment is available for ME/CFS. A consequent self-management with pacing is recommended, and can be supplemented by various relaxation strategies, and sleep hygiene. Symptom-oriented, complex medical support is essential to reduce the severity and frequency of symptoms, and usually includes non-pharmaceutical and pharmaceutical approaches. Psychosocial support may help with implementing pacing and coping strategies, and could achieve adequate measures for education and home care [6, 48, 52]. Experimental strategies targeting the immune, vascular, and nervous system seem promising [53].

With adequate treatment, the course of disease seems to be better in children and adolescents compared to adults, with pediatric recovery rates of 5–83% [6-8, 15-17, 27, 54-61]. Recovery rates in young people have been operationalized by measuring school attendance, symptom frequency and severity, as well as fulfillment of diagnostic criteria at clinical visits or via self-report [55, 62]. In an Australian pediatric cohort, one and two thirds of the patients recovered after 5 and 10 years, respectively, with a median disease duration of 5 (1–15) years in those who recovered [7].

However, in many ME/CFS patients the course of disease is fluctuating, with periods of
deterioration ("crashes"), stabilization, improvement, or relapse-remitting cycles [6, 7, 23]. About
40% of adult patients are estimated to improve over time, but only 5% fully recover [63, 64]. Inferior
outcomes might in part be due to inappropriate management resulting from inadequate diseasespecific knowledge of medical staff [3, 54, 65, 66], a lack of medical services and barriers to the
health care system for patients with ME/CFS [67-69], and stigmatization of patients.
Here we present a first cohort of young ME/CFS patients diagnosed after documented EBV-IM at

152 our MRI Chronic Fatigue Center for Young People (MCFC) and recruited into our prospective 153 MUC-CFS studies for pediatric and adult patients. The MCFC, so far, is the only pediatric university 154 center in Germany specialized on the diagnosis and treatment of children and adolescents with 155 ME/CFS. The MUC-CFS studies provide detailed information on patient demographics, disease

156 phenotypes, and quality of life at the time of diagnosis, as well as during follow-up visits at 6 and 12

157 months. Our primary objective was to assess disease trajectories in these young individuals and to

158 explore potential differences between children and young adults within the cohort.

159 2 Methods

160

2.1 Study Design and Diagnostic Work-up

161 This was a single-center prospective cohort study conducted at a tertiary pediatric university 162 hospital in Munich, Germany. Adolescents and adults until and including the age of 25 years who 163 were diagnosed with ME/CFS after EBV-IM were reassessed at 6 and 12 months by the 164 interdisciplinary team of the MCFC between March 2019 and November 2022.

Documented EBV-IM was defined as a combination of typical symptoms (e.g., fever, fatigue, sore throat, lymphadenopathy, and/or splenomegaly) and typical serology (positive IgM and/or IgG antibodies against EBV viral capsid antigen (VCA) without IgG antibodies against EBV nuclear antigen 1 (EBNA-1), and – in some cases – with documented subsequent EBNA-1-IgG seroconversion).

170 ME/CFS was diagnosed by a multidisciplinary board. Diagnostic criteria were used depending on 171 age: For adults (≥ 18 years) the CCC were used, adolescents had to fulfill either the CCC with a 172 disease duration of at least three months or the less strict criteria of the CDW-R with a disease 173 duration of at least six months. In both cases, PEM had to last for more than 14 hours after mild 174 exertion. Since ME/CFS is a diagnosis of exclusion, all patients underwent thorough medical 175 examinations (laboratory analyses, ECG, UCG, EEG, cMRI, and pulmonary function analyses), 176 including a psychological evaluation. Depending on the clinical presentation supplementary investigations were implemented. Laboratory testing was performed as recommended by Rowe and 177 178 colleagues [6], and a 10-minute standing test (NASA lean test) was conducted to screen for 179 orthostatic intolerance (OI), PoTS, or orthostatic hypotonia (OH).

180

2.2 Standard of Care/Treatment

All patients received a comprehensive, symptom-oriented treatment, the latter of which included both pharmaceutical and non-pharmaceutical interventions to manage symptoms such as pain, sleep disorder, OI and/or psychological comorbidities. They were provided with extensive guidance on self-management and received recommendations for psychosocial support, including adequate measures for adapted school education and home care.

- 186
- 187
- 188

189 **2.3 Ethical Consideration**

Patients and parents (of patients < 18 years) provided informed consent prior to inclusion. The study was approved by the local Ethics Committee (529/18 S-KK, 485/18 S-KK) and conducted in accordance with the Declaration of Helsinki and its later amendments.

193**2.4** Data Collection

2.4.1 Clinical Data

Data were collected from standard clinical records and additional questionnaires from 2019 to 2022. For follow-up visits, questionnaires were mailed to the families one month before a personal or telephone visit. Telephone visits took place when personal visits were not medically indicated, and ME/CFS criteria (CCC for all and CDW-R for adolescent patients) were evaluated.

199

2.4.2 Patient Reported Outcome Measures

The <u>Pediatric Quality of Life Inventory (PedsQL</u>) was utilized to assess HRQoL in pediatric patients. It compromises 20 items and four subscales, namely physical, emotional, social, and school functioning, and has been found to have good internal consistency and reliability [70].

The <u>Short Form-36 Health Survey (SF-36)</u> was administered to all patients to measure HRQoL. It is a 36-item questionnaire that consists of eight subscales (physical functioning, role physical, general health, bodily pain, social functioning, vitality, role emotional, and mental health). Lower scores on each subscale indicate more impairment. The SF-36 has been well-validated and has good internal consistency and discriminate validity. It was designed for children older than 13 years [71]. Younger patients were provided with an in-house supplementary for additional explanations if necessary. Score results are presented as mean ± standard deviation (SD).

The <u>Chalder Fatigue Scale (CFQ)</u> was used as a validated instrument to measure physical and mental fatigue. The scale consists of 11 items, with responses rated on a Likert scale from 0–3. The total score reflects the sum of responses, with a score of 33 indicating most severe fatigue [72]. Score results are presented as mean \pm SD.

The <u>Charité Symptom Inventory</u> was adapted from the CDC Symptom Inventory and rated frequency and severity of typical symptoms of ME/CFS within the month prior to the visit. Scales rated from 0 (not present) to 3 (severe) for the severity and from 0 (not present) to 4 (always) for the frequency of symptoms [73].

The <u>Bell Score</u> is a short and widely used instrument to assess the severity of ME/CFS [74]. Adolescent patients received a modified version with adapted wording (e.g. "school" instead of "work").

221 **2.5** Statistical Analysis

222 The statistical analysis was conducted using R Version from 4.2.1 ("Funny-Looking Kid") [75]. 223 Categorial variables were compared between groups using Fisher's exact test or Pearson's chi-224 squared test, as appropriate. For numeric variables, we used the Wilcoxon rank-sum test or Kruskal-225 Wallis test, as appropriate. Correlation analysis was performed using Spearman's rank correlation 226 coefficient. Cox regression analysis was used to assess the association between independent variables 227 and the time-to first presentation in the MCFC. Repeated measures correlation were used to measure 228 within-subject correlation of patient reported outcome measures [76]. Given the small sample size 229 and lack of adjustment for multiple testing, all P-values were considered exploratory. Level of 230 significance was set to $\alpha = 0.05$.

3 Results

232

3.1 Baseline Demographics and Clinical Characteristics of the Cohort

233 Baseline characteristics are shown in **Table 1**. All 25 patients (80% female) had a history of EBV-234 IM and documented serological findings, indicating EBV primary infection at the time of disease 235 onset. There were no significant differences between adolescents (48%, median age at onset 15, IQR 236 13 -15) and young adult (\geq 18 years) patients (52%, median age at onset 10, IQR 18 - 21) 237 concerning demographics, medical and family history, and current medical care. The median time 238 between EBV-IM and ME/CFS diagnosis at our center was 13.8 months (range 4-84) with no 239 significant difference between males and females (P = 0.272), or adult and adolescent patients 240 (P = 0.596). The time delay from symptom onset to diagnosis was less than 6, 12, and 24 months in 241 1/13 (8%), 5/13 (38%), and 7/13 (54%) adult patients as well as in 1/12 (8%), 5/12 (42%), and 10/12 242 (83%) adolescent patients (Supplementary Figure S1).

243 All adult patients met the CCC and all adolescent patients the CDW-R and/or CCC criteria, as 244 required. Adult and adolescent patients did neither significantly differ concerning the baseline Bell 245 Score nor the SF-36 physical (PCS) and mental health component summary score (MCS). However, 246 adult patients showed significantly higher CFQ scores (adults: 28 ± 4 ; adolescents: 22 ± 5 ; P = 0.006), 247 and significantly lower values (adults: 35 ± 11 ; adolescents: 54 ± 9 ; P = 0.002) in the PedsQL compared 248 to adolescent patients. All adolescents reported regular absences from school, 2/11 (18%) received 249 some form of complementary home schooling and none reported access to distance schooling. Only 250 one patient had a documented degree of disability, and none received medical care at home.

251 24/25 (96%) showed comorbidities led by PoTS in 21/23 (83%) and allergies in 12/23 (48%) of all 252 patients. Two patients examined for PoTS did not complete the NASA-lean test due to severe 253 orthostatic symptoms. One patient presented with an anxiety disorder, and two with mixed anxiety 254 and depressive disorder. 17/24 (71%) of the patients took various supplements, and 11/24 (46%) took 255 prescription-only medications, including three patients on antidepressants. 16/25 (64%) patients 256 remembered another family member with a history of EBV-IM, 10/25 (40%) reported a history of 257 autoimmune disease in their family, and 18/25 (72%) either. 2/25 (8%) reported a family member 258 with ME/CFS.

Our patients had consulted several (median 6, range 1–11) private practice doctors across five different specialties (range 1–11) for ME/CFS symptoms. Additionally, 11/20 (55%) had visited at least one hospital. 7/20 (35%) had previously consulted at least one psychotherapist/psychologist. In

terms of complementary therapies, 9/20 (45%) patients had sought a naturopath, 6/20 (30%)
traditional Chinese medicine, 4/20 (20%) homeopathy, and 5/20 (25%) osteopathy.

264

3.2 Laboratory Findings at Baseline

265 Laboratory findings at the time of diagnosis were primarily unremarkable, and none significantly 266 differed between adolescent and adult patients (Table 2). Besides low vitamin D levels in 14/24 267 (58%) (range 7–29 ng/ml), the most frequent laboratory findings were elevated antinuclear antibodies 268 (ANA) in 14/25 (56%) (range 1:100–1:800), elevated IgE in 7/25 (28%) and mild anemia in 4/25 269 (16%) of all patients. 2/6 (33%) adolescents had mildly positive ANA titers (< 1:160), 2/6 (33%) 270 adolescents and 8/8 (100%) adults showed moderately positive titers (1:160–1:640), and 2/6 (33%) 271 adolescents presented with strongly positive titers (\geq 1:640). ANA titers significantly differed 272 between age groups with higher titers in adolescents (P = 0.015). They did not significantly correlate 273 with disease severity (Bell Score: P = 0.452; SF-36 PF: P = 0.858), and were not significantly 274 different between males and females (P = 0.521). High titers were not associated with clinical signs 275 or any other markers of connective tissue disorders. Herpes simplex virus coinfection was not more 276 frequent in adults than in adolescents (P > 0.999). None of the laboratory findings indicated an 277 relevant differential diagnosis. Neither immunoglobulin serum levels nor immunophenotyping of 278 peripheral blood lymphocytes did show any evidence of primary immunodeficiency (Supplementary 279 Table S1).

280 Results from EBV serology, EBV PCR, and EBV IgG immunoblot at baseline visit are displayed 281 in Table 3. Adolescents and adults did not show significant differences. Quantitative analyses of 282 EBV viral load using real-time PCR did not detect EBV DNA in the plasma of any patient. 8/20 283 (40%) patients showed EBV DNA in peripheral blood cells (5/8 very low titers, 1/8 17.7 Geg/10^5, 284 1/8 70.1 Geq/10^5, and 1/8 121.8 Geq/10^5), and 14/25 (66%) had EBV DNA in throat washes. The 285 detection of EBV DNA in throat washes did not significantly correlate with disease severity (Bell 286 Score: P = 0.686; SF-36 PCS: P = 0.871). All patients showed anti-EBV-VCA IgG as expected, 287 23/25 (92%) demonstrated anti-EBNA-1 IgG, and 6/25 (24%) anti-EBV-VCA IgM. The detection of 288 anti-EBV-VCA IgM did not significantly correlate with disease severity (Bell Score: P = 0.877; SF-289 36 PCS: P = 0.788). Results of EBV immunoblots revealed IgG antibodies against early antigens 290 (EA) p54 and p138, the immediate early antigen BZLF1, virus capsid antigens (VCA) p23 and p18, 291 and the latency antigen EBNA-1 in 8/25 (32%), 5/25 (20%), 18/25 (72%), 23/25 (92%), 24/25 (96%), 292 and 22/25 (88%) patients, respectively.

3.3 ME/CFS Criteria at Follow-up Visits

Follow-up data were available at 6 months after the diagnosis of ME/CFS from 22/25 (88%) patients, including 10/13 (77%) adults and 12/12 (100%) adolescents, and at 12 months from 20/25 (80%) patients, including 9/13 (69%) adults and 11/12 (92%) adolescents. Reasons for drop out were recovery (one adolescent), worsening of symptoms (one adult) and unknown (two patients).

299 The changes in CCC and CDW-R criteria fulfilment are visualized in **Fig. 1**. Of the adult patients, 300 seven fulfilled the CCC at all three visits. One became CCC negative at 6 months but met the CCC 301 criteria again at 12 months (Fig. 1A). Six adolescent patients were still positive for the CDW-R 302 criteria at 6 months and only four at 12 months follow-up. One patient became CDW-R negative at 6 303 months but met the CDW-R criteria again at 12 months (Fig. 1B). By 6 months one and by 12 304 months three additional pediatric patients had turned 18 years old, and therefore the CDW-R criteria 305 were not applicable anymore (indicated by N/A in Fig. 1C). The CCC criteria were fulfilled by 8/12 306 (67%) of the adolescents at the first visit, by 4/12 (33%) at the 6-month visit and by 4/11 (36%) at the 307 12-month follow-up. Two adolescent patients who were CCC positive at 12 months had been 308 negative at the previous visits (Fig. 1C). At the 6-month follow-up, 7/12 (58%) adolescents met 309 either the CCC or the CDW-R criteria, and 5/11 (45%) met either of both at the 12-month follow-up 310 (Fig. 1D). The five patients who did not fulfill CCC or CDW-R criteria anymore, still fulfilled some 311 domains of the CCC or CDW-R criteria and therefore showed only partial remission of postviral 312 disease. For two patients the only persisting symptom was OI. One patient reported fatigue with 313 limitations in daily life and headaches. Three patients had several persisting symptoms but did not 314 complain of fatigue with limitations in daily life anymore.

All patients in partial remission were adolescents (P = 0.005) and had a relatively short illness duration of less than three years (mean 24 months, range 15–34 months). They had significantly less fatigue (CFQ Likert score: P = 0.001) and higher HRQoL (PedsQL: P = 0.026) at diagnosis, compared to patients without partial remission (**Supplementary Table S2**). Further, patients in partial remission did not significantly differ in any of the other baseline characteristics and laboratory parameters tested, including EBV serology, EBV PCR or EBV IgG Immunoblot (**Supplementary Table S2 and S3**).

322 **3.4** Number, Frequency, and Severity of Symptoms at Follow-up Visits

323 At the baseline visit, patients presented with 27 ± 5 symptoms in mean (\pm SD), with 15 ± 5 occurring 324 at least frequently (**Fig. 2**). The most common symptoms reported at least frequently (3 or 4 on Likert

325 scale) were fatigue (96%), performance limitations in daily life (96%), need for rest (92%) and PEM 326 (83%). The most common severe (3 on Likert scale) symptoms were post-exertional malaise (46%), 327 stress intolerance (38%), fatigue (33%), performance limitations in everyday life (33%) and 328 unrefreshing sleep (33%). The number of symptoms and the severity and frequency of individual 329 symptoms did not significantly change between the baseline and two follow-up visits 330 (Supplementary Table S4). Adults reported slightly more symptoms (29±3) than adolescents (25±7, 331 P = 0.084). Symptoms occurring at least frequently were more common in adults than adolescents 332 $(19\pm6 \text{ vs. } 12\pm3, \text{ P} = 0.006)$. This difference was also evident at the two follow-up visits 333 (Supplementary Table S5).

334

3.5 Patient-Reported Outcome Measures

335

3.5.1 Chalder Fatigue Scale

Fatigue was further characterized by the CFQ. At the first visit, the patients' CFQ Likert score was 25±5, and did not significantly change at the follow-up visits. While adult patients showed a moderate worsening from the first (28±4) to the follow-up visits (6-months: 28±4; 12-months: 29±4), adolescent patients showed a moderate improvement from the first (22±5) to the follow-up visits (6months: 19±9; 12-months: 18±9) (**Table 4, Fig. 3A**). At all visits, adolescent patients had significantly less fatigue than adults (first visit: P = 0.006; 6-months: P = 0.016; 12 months: P = 0.003) (**Supplementary Table S6**).

343

344 3.5.2 Bell Score

The median Bell Score was 40 (IQR: 30–50) and did not significantly change at the follow-up visits (P = 0.384). Adults had a median Bell Score of 30 at all visits. Adolescents' Bell Score moderately, but not significantly, improved from the first (median: 50, IQR: 40–50) to the 6-month and 12-month follow-up visits (both median: 60, IQR: 40–80) (P = 0.232) (**Table 4, Fig. 3B**). The Bell Score of adolescents was significantly better than adults' Bell Score at all visits (first visit: P = 0.019; 6 months: P = 0.019; 12 months: P = 0.007) (**Supplementary Table S6**).

351

352 **3.5.3 Short Form-36**

353 SF-36 summary and subscales did not significantly change from the first to the two follow-up 354 visits, neither for all nor for adult or adolescent patients separately. However, adolescents had a 355 significantly better physical component summary score at the 12-month visit than adults (P = 0.013)

356 (Table 4, Fig. 3C and 3D). At the first visit adolescents were significantly better concerning physical 357 functioning (P = 0.039) and vitality (P = 0.012), at the 6 months visit at physical functioning (P = 0.039) 0.039), pain (P = 0.039), general health (P = 0.032), social (P = 0.025), and mental health (P = (P = 0.032)). 358 359 0.025), and at the 12 months visit at physical functioning (P = 0.019) and vitality (P = 0.010). There 360 was no significant difference in the mental health component summary score at none of the visits 361 (Supplementary Table S6). In the self-perceived health transition 6/10 (60%) adolescents and none 362 of the adults rated their general health at least somewhat better than in the previous year at the 363 12 months visit (Supplementary Table S7).

- 364
- 365

3.5.4 Pediatric Quality of Life Inventory

The PedsQL total score did not significantly change from the first to the two follow-up visits. The subscale scores were lowest for the school functioning and physical functioning domains, and highest for social functioning. School functioning in adolescents was the only subscale that significantly increased over time (P = 0.03) (**Table 4, Fig. 3E**). Except for the school subscale at the first 6-month visit and emotional subscale at the 12-months visit, all subscales were significantly different at all visits between adults and adolescents (**Supplementary Table S6**).

For all patients the greatest correlation between different patient-reported outcome measures (CFQ, Bell Score, PedsQL, SF-36) was between CFQ and PedsQL (r = -0.76, P < 0.001), indicating that more severe fatigue was associated with lower HRQoL (**Figure 4**). The most prominent difference between adults and adolescents was that CFQ and Bell Score correlated significantly for adolescents but not for adults (adults: r = -0.29, P = 0.209; adolescents: r = -0.77, P < 0.001).

377

378 **3.6 Description of Patients in Partial Remission**

At 12 months, results from PROMs for patients in partial remission compared to patients not in partial remission at this time point were median Bell Score 80 (range 40 – 100) versus 40 (range 20 – 80), mean CFQ Score 12.4 (SD 6.7) versus 24.4 (SD 6.2), PedsQL total score 76.1 (SD 16.8) versus 46.6 (SD 15.8), the SF-36 physical health summary score 44.7 (SD 7.7) versus 28.9 (SD 11.5), and the SF-36 mental health summary score 50.9 (SD 7.1) versus 42.9 (SD 10.4). These results indicate that not any more fulfilling the diagnostic ME/CFS criteria does not exclude an ongoing impairment of daily function.

386 **4 Discussion**

This is the first report on adolescents and young adults with ME/CFS following EBV-IM in Germany. The study provides baseline demographics as well as various clinical data at the initial visit and at two follow-up visits at 6 and 12 months after ME/CFS diagnosis, including diagnostic scores, frequency and severity of symptoms, HRQoL, and physical as well as mental functioning.

ME/CFS is recognized as a debilitating disease which fundamentally impacts social participation, education and HRQoL [6, 7]. However, so far data on ME/CFS in pediatric cohorts have mostly been collected in the US, the UK and Australia, and to our knowledge no pediatric study from Germany is available [6-8, 15-17, 27, 54-61]. While some prospective pediatric studies assessed the occurrence of ME/CFS following EBV-IM [18-20], to our knowledge none evaluated several diagnostic scores requiring PEM longitudinally and/or compared data from adolescents and young adults.

397 398

Baseline Demographics and ME/CFS Diagnosis

Our youngest patient was 14 years-old which was in line with the published ME/CFS age peak at 15–40 years [12, 48, 49]. The observed female predominance (80%) in our cohort is a widely recognized phenomenon in post-pubertal ME/CFS patients with 3–4 times higher prevalence reported in adolescent girls than boys [6, 21, 49].

403 At the initial visit, all adult patients met the CCC and all pediatric patients met the CDW-R and/or 404 CCC criteria as was required for ME/CFS diagnosis in this study. However, due to the absence of 405 pain (n=3) or neurocognitive manifestations (n=1), 4/12 (33%) of the adolescents did not fulfill the 406 CCC, supporting the use of more sensitive diagnostic criteria for pediatric patients [77]. Different 407 adaptations have been made for diagnosing ME/CFS in children and adolescents [6, 51, 54] of which 408 the CDW-R and Jason's pediatric case definition (here abbreviated as PCD-J) require PEM as an 409 essential symptom, in line with current recommendations [54, 78]. The largest pediatric ME/CFS 410 follow-up study used the polythetic Fukuda criteria with the modification that the presence of PEM 411 was mandatory [7]. However, most other pediatric follow-up studies used the original polythetic 412 Fukuda criteria or the even broader Oxford criteria for diagnosing ME/CFS [7, 8, 15-17, 27, 55-61] 413 and might thus have included individuals without PEM. Data on the prevalence and clinical 414 outcomes of post-infectious ME/CFS in children and adolescents have thus to be reevaluated. In our 415 ongoing prospective Munich infectious mononucleosis (IMMUC) study [79] as well as the 416 Multicenter Long COVID registry (MLC-R) [80] and the German ME/CFS registry (ME/CFS-R) 417 [81] we are investigating the CCC together with the CDW-R, the PCD-J and the systemic exertion

intolerance disease (SEID) criteria, the latter of which have been recommended for diagnosing
ME/CFS in any group by the former Institute of Medicine (IOM) [49], the European Network on
ME/CFS research (EUROMENE) [48], and the Centers of Disease Control and Prevention (CDC)
[82].

422 In the present study the median diagnostic delay between the onset of EBV-IM and the diagnosis 423 of ME/CFS was more than one year (13.8 months). This is in line with most reports from other 424 countries, indicating long and difficult patient journeys before initial expert consultation or ME/CFS 425 diagnosis of pediatric [3, 65] and adult patients [54, 66]. We did not find any association of gender, 426 age, or disease severity with time to diagnosis according to previous studies [65, 83]. Published 427 reasons for the long diagnostic delay in ME/CFS include little knowledge of families and primary 428 care providers, the requirement for comprehensive differential diagnosis, as well as negative attitudes 429 and beliefs by primary care physicians and psychologists [54, 83, 84]. In Germany, the lack of 430 ME/CFS specialists is most likely contributing to this issue and, due to a higher prevalence of 431 ME/CFS, might affect the adult age-group even more than adolescents and children. Young adults in 432 our study showed a longer prior disease duration compared to children, which might also reflect 433 challenges during transition from pediatric to adult health care services [85].

434

435 **Postural Tachycardia Syndrome and Other Comorbidities**

In our cohort, only few patients demonstrated any other medical diagnosis prior to the onset of ME/CFS but many showed current comorbidities. The latter included PoTS (83%), allergies (48%), and psychiatric diagnoses (12%). The low prevalence of the latter was in line with other reports on pediatric ME/CFS [6, 86, 87]. In general, comorbidities were more prevalent in studies with adult ME/CFS patients (79–80%) [23, 88].

441 PoTS has been previously reported in pediatric and adult ME/CFS patients with varying 442 prevalence [6, 54]. 25/26 adolescents with ME/CFS experienced severe orthostatic symptoms 443 associated with syncope (7/25), orthostatic tachycardia with hypotension (15/25), and orthostatic 444 tachycardia without significant hypotension (3/25) during a head-up tilt table test [89]. In adult 445 ME/CFS patients, the prevalence of PoTS was generally reported to be high with reported rates 446 ranging from 5.7% to 70% [49]. The large span of percentages might be due to different cohorts as 447 well as to different PoTS tests and PoTS case definitions [90]. However, PoTS is a frequent post-448 infectious phenomenon in adolescents and thus, not unexpectedly, a frequent comorbidity of 449 ME/CFS [91]. A timely PoTS diagnosis is important since it impacts on orthostatic performance in

450 school and other daily activities and can be treated by various non-pharmaceutical and 451 pharmaceutical interventions.

452

453 **Reported Lack of Medical Care**

454 Although ME/CFS is defined as a disorder that significantly reduces or impairs daily activities, 455 only one of our patients had previously received a certificate of disability and none was supported by 456 adequate medical devices or home care, together reflecting poor medical care and barriers to 457 specialized support as outlined in previous studies [67-69]. A large proportion of our patients took 458 various dietary supplements and/or had received complementary medical treatment which both had 459 also been demonstrated for other pediatric and adult ME/CFS cohorts and may, in addition, reflect a 460 lack of standard medical support [7, 92]. The lack of adequate medical care is especially remarkable 461 regarding the large number of medical consultations with ME/CFS symptoms prior to diagnosis 462 reported by our patients and in other studies on ME/CFS [67, 69].

All pupils in our study reported on frequent school absences, and, remarkably, only a minority had received any educational assistance such as home or digital schooling. These findings were in line with earlier studies indicating that ME/CFS is a frequent cause of prolonged school absences and severely affects social participation and education of young people [3-8]. This is particularly concerning, since pediatric patients with ME/CFS reported that remaining engaged in an education system that flexibly accommodated their illness and aspirations was crucial for their long-term functioning [7, 93, 94].

470

471 Laboratory Findings

472 So far, no biomarker for ME/CFS has been established. Symptom-oriented laboratory analyses are 473 recommended to evaluate potential differential diagnoses and usually show unremarkable results in 474 ME/CFS [6, 54]. This was also true for our cohort. Some patients demonstrated minor deviations of 475 hematological and immunological parameters, including mild anemia, lymphocytosis, and/or 476 neutropenia as well as mild changes in peripheral lymphocyte subtypes and serological markers of 477 inflammation, autoimmunity, and/or allergies. More than half of the patients showed elevated ANA 478 titers, as previously reported for many ME/CFS patients, without clear evidence of distinct 479 underlying autoimmune diseases [7]. The proportion of positive titers (56%) was greater than 480 expected from a previous report with 34% positive titers in this age group [7]. Although, it is not 481 unknown to have moderately elevated titers without evidence of autoimmune disorders in pediatric 482 rheumatology. Almost a third had elevated IgE levels but clear associations between IgE levels and

483 ME/CFS have not been found in earlier studies [95]. Remarkably, the majority of patients presented 484 with vitamin D deficiency. However, low serum concentrations of vitamin D did not appear to be a 485 contributing factor to the level of fatigue in another cohort of ME/CFS patients [96].

486 As expected, all patients showed anti-EBV VCA IgG as an indicator of previous EBV infection, 487 with some individuals lacking an anti-EBNA-1 seroconversion. The findings of undetectable EBNA-488 1 IgG as well as of detectable anti-EBV VCA IgM, anti-EBV EA IgG, EBV DNA in throat washes 489 were not more frequent in our cohort than reported for the general population [97-100]. Detectable 490 EBV DNA in blood cells was more frequent than in a U.S. cohort aged 1 - 97 years (median 42) 491 years) without EBV-associated disorder [101]. In sum, we found no significant correlation between 492 EBV-specific serological findings or detection of EBV DNA with disease severity or physical 493 functioning. These findings were in line with previous research that has not found a distinct pattern 494 of EBV-specific routine virological results in ME/CFS patients [42, 102]. However, findings 495 regarding EBV-specific immune responses in patients with ME/CFS are inconsistent, and EBV 496 antigen mimicry might well contribute to pathogenic autoimmunity as shown by us in more 497 comprehensive EBV-specific immunological analyses [35, 44, 46, 103-107]. EBV and herpes viruses 498 in general have been discussed as a cause or perpetuating factor of ME/CFS, while no stringent 499 causal association has been proven yet [41, 42, 102].

500

501 **Partial Remission at Follow-up**

In a large Australian cohort aged 16 to 77 years, post-infectious fatigue triggered by EBV, Q-fever or Ross River virus was transient in most cases, as indicated by 35%, 27%, 12%, and 9% of patients affected at 1.5, 3, 6, and 12 months after the onset of symptoms [19]. However, most concerningly, an increasing number of studies on long-term sequelae of coronavirus disease 2019 (COVID 19) currently indicate that most patients affected by post-COVID syndrome at 3 months were still not recovered after 12 months [22, 108].

Most studies specifically assessing fatigue and ME/CFS in young people after EBV-IM evaluated no longer follow-up periods than 6 months, some relied on self-reported ME/CFS or did not require PEM for ME/CFS diagnosis, and none compared the course of disease in adolescents and very young adults [19, 20, 24-31]. However, according to a more favorable prognosis in younger people, the proportion of ME/CFS after EBV-IM in adolescents in the US decreased significantly over time, with 12.7%, 7%, and 4% at 6, 12, and 24 months [18, 19].

514 In our study the median time since onset of EBV-IM was 13.8 months at the first visit, indicating 515 that some patients might recover over time during the study period. Most remarkably, the majority of

516 our adolescent patients did not fulfill the criteria for ME/CFS diagnosis any more at 12 months after 517 the first visit, while all adult patients still met the CCC. The different health trajectories for 518 adolescent and adult patients were also evident in the self-perceived health transition item of the SF-519 36 at 12 months after the first visit, with 40% and 20% of children rating their general health as much 520 better or somewhat better, and 45% and 22% of adults much worse or somewhat worse than in the 521 previous year, respectively. Furthermore, over the whole study period symptom load (see below) and 522 school functioning (PedsQL) significantly improved in adolescents while remaining stable or 523 worsening in adults.

524 These findings were in line with compelling evidence indicating a better ME/CFS prognosis of 525 children and adolescence compared to adults, with pediatric studies reporting recovery of up to 83% 526 [6-8, 15-17, 27, 54-61]. A large pediatric follow-up analysis from Australia indicated recovery in 527 50% of the cases at five and 68% of the cases at ten years after disease onset with a median disease 528 duration of five (range 1-15) years [7]. Dramatic improvement was reported to be more likely within 529 the first four years [6]. Accordingly, all patients in partial remission in our cohort had an illness 530 duration of less than three years. Although some adult patients, in general, may also experience 531 significant improvements over time, a systematic review indicated that prognosis in adults is fairly 532 poor, with only a minority of adult patients experiencing full recovery [109].

533 Importantly, only two of our pediatric patients were largely free of ME/CFS symptoms (except 534 OI) at their last visit and all remaining patients, independently of their state of partial remission, still 535 reported symptoms from several domains of the diagnostic criteria. Furthermore, we observed some 536 fluctuation of disease load over time, with some patients no longer meeting the diagnostic criteria at 537 6 but again at 12 months, thereby reflecting unstable and unpredictable dynamics of remissions. 538 Remissions and relapses were reported to be common in pediatric ME/CFS patients and can occur for 539 example after overexertion or additional infectious illnesses [6]. Our findings support the 540 recommendation that pediatric patients must be offered thorough follow-up evaluations and 541 continuous medical care even if they do not any longer fulfill the diagnostic ME/CFS criteria.

It remains challenging to measure recovery from ME/CFS, especially in pediatric patients. Previous pediatric studies have established recovery through various measures such as school attendance, fulfillment of diagnostic criteria, or self-report [55]. However, available studies have used various diagnostic criteria, different follow-up periods (ranging from six months to 13 years), and different inclusion criteria, thereby limiting direct comparisons. Moreover, what young people with ME/CFS consider as "recovery" can largely differ [7] and patient coping at any age might challenge measuring recovery [110].

549 Risk factors for prolonged disease after EBV-IM and for ME/CFS duration in general are not yet 550 clear. US college students who developed ME/CFS after IM had more physical complaints but not 551 more perceived stress, depression, anxiety, or abnormal coping before the onset of IM [20]. Some 552 studies have associated prolonged symptoms after EBV-IM with older age and severity of acute IM, 553 others have identified initial pain severity, autonomic symptoms, lower mental health scores, higher 554 anxiety and depression scales, more days-in-bed, female gender, and distinct laboratory changes 555 (CRP, vitamin B12, cytokines) during EBV-IM as risk factors for the development of ME/CFS. 556 However, the case definitions of ME/CFS varied in early studies, findings have been inconsistent, 557 and it is unknown, whether risk factors of ME/CFS onset also impact on the duration of ME/CFS [20, 558 24, 28-30, 47, 111]. Several factors have been suggested to affect the prognosis of ME/CFS in 559 general, including age, female gender, fatigue severity at disease onset, PEM severity, severity of 560 ME/CFS symptoms, comorbidities, illness duration, life stressors, and lower socioeconomic status [6, 561 15, 16, 84, 112, 113], although findings so far remained inconclusive. With better initial test results 562 and better final outcomes of adolescents compared to adults, our findings might support younger age, 563 shorter disease duration, a better Bell Score, as well as less severe fatigue (CFQ) at first presentation 564 as potential markers for a more favorable course of disease although, of course, the number of 565 patients was by far too small to draw any final conclusions.

The interpretation of published data on ME/CFS outcome is additionally challenged by the fact that in many ME/CFS cohorts the initial trigger is less well characterized than in our cohort. An Australian ME/CFS cohort included 80% post-infectious cases, with 40% of the cases described as triggered by EBV-IM, although only 25% had documented serological changes at onset [7]. Other pediatric studies have reported between 23% and 90% of perceived infectious triggers [15-17, 114] or provide no further information on any events at onset [8, 27, 56]. Some studies, furthermore, included patients with dominantly gradual onset and thus no distinct trigger [5, 17].

573

574 Symptom Load over the Study Period

575 Our patients reported a wide range of symptoms that persisted over time, with overall little change 576 in severity or frequency. The ME/CFS core symptoms PEM, fatigue, need for rest, performance 577 limitations in daily life, unrefreshing sleep, concentration problems, and mental exhaustibility were 578 reported to occur at least frequently and to be at least severe by a substantial proportion of patients. 579 The results of this study highlight the interindividual variability of dominant symptoms as well as the 580 fluctuation of intraindividual symptoms over the course of a year. In general, symptoms in pediatric

581 ME/CFS are reported to fluctuate more than in adults [6]. However, due to the small size of our 582 cohort we did not investigate this issue in more detail.

583 In adolescent patients, fewer symptoms were reported at 6 and 12 months compared to the initial 584 visit, which is in line with partial remission of some patients. Conversely, the number of symptoms 585 reported by adults remained stable over the whole study period. It is also worth noting that adults 586 consistently reported more symptoms and almost twice as many frequent symptoms than adolescents 587 at all visits. This supports the recommendation to quantify symptoms at the time of diagnosis and 588 might suggest prioritizing frequent symptoms in treatment protocols. Quantifying frequency and 589 specificity was recommended to increase the specificity of ME/CFS diagnosis [115], since mild 590 forms of most ME/CFS symptoms frequently occur in the general population. In our cohort a 591 substantial number of symptoms were also reported to occur only sometimes or rarely, or to be of 592 mild severity.

593

594Health-Related Quality of Life

595 Previous studies have shown that children and young adults with ME/CFS experience a severe 596 illness that fundamentally affects their social life and education, and is associated with a poorer 597 HRQoL than found in peers with other chronic diseases including asthma, diabetes mellitus, epilepsy, 598 and cystic fibrosis [7, 9-11]. Remarkably, the PedsQL results were very similar between our 599 adolescent cohort and adolescent ME/CFS patients in the US, Australia or Norway [9, 10, 116, 117]. 600 Furthermore, our adolescent sample also displayed the same relative distribution of subscales as 601 published cohorts, with patients reporting worse HRQoL in physical and school function and better 602 HRQoL in social and emotional functioning.

Adolescents in our cohort reported moderate improvements on the total score, physical and 603 604 psychosocial score, as well as significant improvements on the school domain, while social and 605 emotional quality of life seemed stable. The improvements in the total score, psychosocial score, and school score were greater than a suggested minimal clinically meaningful difference in PedsQL 606 607 results from pediatric cohorts [118]. However, no clinically meaningful difference was specifically 608 suggested so far for patients with ME/CFS. The improvements observed in HROoL of our adolescent 609 cohort are in line with the fact that some of the patients experienced a partial remission. However, 610 intensive school counselling by our team might have contributed to a better school situation and 611 changes in HRQoL.

612 Most concerningly, we found little evidence for improved HRQoL in young adults, apart from 613 improvements in the emotional and social subdomains possibly due to the implementation of

614 specialized psychosocial and medical care. Young adults in our cohort reported much lower HRQoL 615 compared to adolescents from our and other studies. We are not aware of any other studies assessing 616 HRQoL in very young adults specifically, but studies in adult ME/CFS patients in general have 617 consistently reported very low HRQoL [119, 120].

The transition from adolescence to young adulthood as well as from pediatrics to adult patient medicine can be particularly challenging for young people with ME/CFS, with individuals facing a range of uncertainties regarding health care, education, financials, and contact to peers. These factors may be contributing to the lower HRQoL reported by young adults compared with adolescents in our study. Unrevealing the additional age-specific risk factors for chronification will be crucial for developing effective strategies to improve the well-being of this most vulnerable group of people with post-infectious syndromes and ME/CFS.

625 Few studies have investigated risk factors for worse HRQoL in adolescents with ME/CFS and 626 found high frequency of PEM, cognitive symptoms, regular school absence, delayed school 627 progression, and attending physical therapy or rehabilitation as possible risk factors. After diagnosis, 628 support of school personal, regular school attendance, and participation in leisure activities have been 629 associated with higher HRQoL [10, 121]. The findings regarding a possible risk contribution of 630 depressive symptoms were inconsistent [10, 117, 120, 121]. Furthermore, it was reported that 631 adolescents meeting the Fukuda and IOM criteria displayed worse HRQoL than adolescents only 632 satisfying the Fukuda criteria, suggesting that criteria requiring PEM might select patients with worse 633 HRQoL [10]. The fact that the very strict CCC have been used to diagnose ME/CFS in our adult 634 patients might have contributed to the findings of lower HRQoL, worse physical functioning, and 635 longer disease duration in this age group. Additionally, a selection bias must be considered, as the 636 sample of young adults in this study may have been skewed by the fact that they sought treatment at 637 a pediatric clinic, potentially indicating a higher level of desperation or urgency in seeking medical 638 care.

Altogether, it is difficult to interpret the trajectories of HRQoL in this study, as to our best knowledge, no other longitudinal evaluations of HRQoL in children or young adults with ME/CFS are available, and since no matched healthy controls have been evaluated during the study period. Especially a possible impact of fears elicited by the COVID-19 pandemic or by restrictions thereof during the course of disease cannot be excluded.

644

645 **Strengths and Limitations**

646 As an important strength our study presents longitudinal data on ME/CFS cases that manifested 647 after serologically confirmed EBV-IM. Confirming an infectious onset or even a specific infectious 648 trigger of ME/CFS years after its occurrence can be very challenging, since self-reports are not 649 reliable and ordering former medical documents is time-consuming, and in many cases not 650 successful. This is especially true in cases of EBV-IM, where retrospective diagnoses rely on 651 sufficient serological evidence of EBV primary infection documented together with typical clinical 652 signs and symptoms. We did not include patients with probable EBV-IM (e.g. typical clinical signs 653 only) in this article which we will report on together with a young cohort of ME/CFS patients 654 triggered by other infectious diseases. Our study supports the reassurance of younger adolescents that 655 improvement of ME/CFS following EBV-IM is not uncommon, even if it takes months or years, and 656 that remission is possible, also it cannot be guaranteed, as suggested by others [6, 7, 18].

657 A second strength of our study is the inclusion of very young adult patients together with 658 adolescents. The former population often gets lost from pediatric as well as non-pediatric studies due 659 to age-specific challenges on either side, including studies on post-viral syndromes. For example, a 660 recent longitudinal study on long-term recovery from SARS-CoV-2 infection in children specifically excluded participants from follow-up after their 18th birthday and thereby possibly generated a bias 661 662 towards lower prevalence of complex and severe symptoms [122]. For patients older than 17 years 663 pediatricians mostly cannot provide follow-up due to regulatory issues, and non-pediatric care takers 664 might face barriers to getting a complete medical history and/or to helping with issues regarding 665 school, academic career, parents, siblings, or peers. Unfortunately, we witnessed difficulties of very 666 young adults with ME/CFS to be adopted by local general practitioners which most likely further 667 impaired their clinical outcome. In our center we regularly see young people up to an age of 20 to 668 facilitate the transition within age-specific borders of medical care and to investigate age-specific 669 resilience and risk factors.

Third and importantly, we provide data on ME/CFS cases that were diagnosed by clinical criteria requiring PEM as a hallmark of ME/CFS and as recommended by the EUROMENE [48] and others [49, 50, 52]. Moreover, we compare the fulfillment of the CCC and the less strict criteria of the CDW-R in our adolescent cohort, while many earlier studies reported on EBV-triggered ME/CFS cases that were diagnosed by the polythetic Fukuda or even the Oxford criteria which both do not essentially require PEM.

We furthermore provide detailed information on clinical phenotypes, including the frequency and severity of typical ME/CFS symptoms, a comprehensive set of data from various well-established PROMs evaluating fatigue, daily functioning, or HRQoL (CFQ, Bell Score, PedsQL, SF-36), and

various laboratory results, including peripheral immunophenotypes, EBV serology, and EBV DNAload.

681 Overall, our study adds to the current understanding of ME/CFS in young people and highlights
682 the importance of an early diagnosis as well es of a thorough longitudinal evaluation of patients with
683 ME/CFS following EBV-IM.

684

685 The study has several limitations that must be considered when interpreting the results. First, a 686 potentially multi-facetted selection bias is limiting the generalizability of results. Since our center is 687 the only specialized pediatric ME/CFS clinic in Germany, before admission patients are faced with 688 significant waiting times and with time-consuming prerequisites such as answering questionnaires 689 and providing previous medical results. Additionally, many patients must travel a significant distance 690 to reach our clinic and therefore the study sample is most likely skewed towards individuals with 691 moderate or less severe ME/CFS and to families than can afford travelling. Moreover, our cohort was 692 limited to children and adolescents registered in upper school services and to Caucasian patients, 693 which might suggest that individuals from other groups may be underrepresented, possibly due to 694 barriers within the health care system; given the lack of knowledge on ME/CFS, it often requires 695 significant effort of patients and their families to get specialized care and not rarely the patients' 696 journeys involve multiple healthcare professionals.

697 Second, the sample size of the study and the number of individuals who experienced partial 698 remission is relatively small, which can affect the statistical power of the analyses and the 699 generalizability of the results.

Third, although the drop-out rate of 20% at the assessment after 12 months was deemed acceptable, it is important to acknowledge that some patients were lost to follow-up, which could introduce bias and potentially reduce the overall representativeness of our sample. Based on our experience, discontinuation in ME/CFS studies may not be missing at random, as some patients may be unwilling to continue participating due to perceived improvement, while others may feel too ill to continue.

In addition, this study was limited in its ability to investigate risk factors prior to diagnosis of ME/CFS, since patients were registered after the onset of this disease. Our study focused on examining risk factors that might have contributed to the maintenance of ME/CFS. However, it is important to note that additional prospective studies, such as those in US college students, are needed to further explore potentially predisposing factors indicating an increased risk or resilience without recall bias [20].

As another limitation it should be noted that the 12 months follow-up period may not provide enough information to evaluate the long-term prognosis of ME/CFS, particularly in young adults. Longer follow-up data would be beneficial, especially since young adults do not appear to show significant improvement one year after diagnosis.

Finally, the lack of a matched control group in this study makes it challenging to interpret some

results, for example changes in HRQoL over time or frequency and severity of ME/CFS symptoms

that are non-specific and common in the general population.

719 While this study provides valuable insights into the clinical course of a complex chronic disease in 720 young people, these limitations suggest that caution is necessary when interpreting the results. Future

721 studies with larger sample sizes, longer follow-up periods, and appropriate control groups are

necessary to further validate and extend these findings.

723 Conclusions

724 In conclusion, ME/CFS after EBV-IM is a debilitating disease that results in severe functional 725 impairment and poor quality of life for both adolescents and young adults in Germany. Access to 726 healthcare and treatment is a fundamental barrier for patients with this condition. Laboratory findings 727 were inconclusive, and there was no evidence to suggest that EBV perpetuates the disease. While 728 patients with ME/CFS often experience a variety of fluctuating symptoms, it is possible that the 729 frequency and severity of core symptoms may be more significant in predicting prognosis. Young 730 adults reported more symptoms, greater physical impairment, and worse quality of life than 731 adolescents. While some pediatric patients showed signs of improvement over the study period, 732 young adults tended to have a poor prognosis, underscoring the need for special attention when 733 taking care for this age group. There is a clear need for more research to clarify the reasons for the 734 different health trajectories and to identify prognostic markers that allow for an evidence-based 735 stratification of multi-professional and multi-modal longitudinal care. Further research is also 736 necessary to better understand the pathomechanisms of the disease, identify reliable biomarkers for 737 early diagnosis, and to develop effective treatments that can improve outcomes and support recovery.

- 738 Data Availability Statement
- 739 Data is available upon reasonable request.

740 Ethics Statement

Patients and parents (of patients < 18 years) gave written and informed consent prior to inclusion.
The study was approved by the local Ethics Committee (529/18, 485/18) and conducted in
accordance with the Declaration of Helsinki.

744 Author Contributions

R.P., P.M., T.H., K.G., and U.B. designed the study. R.P., P.M., T.H., H.Z., Y.M., K.W, J.P., and
A.L. acquired data and investigated patients. R.P., S.M.H., L.M, and U.B. analyzed the data. R.P.,
M.H., L.M., and U.B. drafted and reviewed the manuscript. K.G. and U.B. supervised the work. All
authors discussed the results and commented on the manuscript.

749 Funding

750 This work has been supported by the Lost Voices and Weidenhammer-Zoebele foundations.

752 Acknowledgments

753 We thank all patients who participated in this study and their parents for supporting their 754 participation.

755 **Conflict of Interest**

U.B. received research grants from Federal Ministry of Education and Research (BMBF), the
Federal Ministry of Health (BMG), the Bavarian Ministry of Health and Care (StMGP), the Bavarian
Ministry of Science and Arts (StMWK), the German Center for Infection Research (DZIF), the
People for Children (Menschen für Kinder) Foundation, the Weidenhammer-Zöbele Foundation, the
Lost-Voices Foundation, and the ME/CFS Research Foundation.
C.S. was consulting Roche, Celltrend, and Bayer; she received support for clinical trials by Bayer,

762 Fresenius, and Miltenyi, honoraria for lectures by Fresenius, AstraZeneca, BMS, Roche, Bayer, and

763 Novartis, and research grants from the German Research Association (DFG), the BMBF, the BMG,

the Weidenhammer-Zoebele Foundation, the Lost-Voices Foundation, and the ME/CFS Research

Foundation.

All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

768		References
769		
770 771 772	1.	Unger, E.R., et al., Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study, Am J Epidemiol. 2017. 185 (8): p. 617-626
773	2.	Pendergrast, T., et al., Housebound versus nonhousebound patients with myalgic
774		encephalomyelitis and chronic fatigue syndrome. Chronic Illness, 2016. 12 (4): p. 292-307.
775	3.	Crawley, E. and J.A. Sterne, Association between school absence and physical function in
776		paediatric chronic fatigue syndrome/myalgic encephalopathy. Arch Dis Child, 2009. 94(10):
777		p. 752-6.
778	4.	Van Geelen, S.M., et al., <i>Adolescent Chronic Fatigue Syndrome</i> . 2010. 164 (9).
779 780	5.	Nijhof, S.L., et al., Adolescent Chronic Fatigue Syndrome: Prevalence, Incidence, and Morbidity, PEDIATRICS, 2011, 127 (5): p. e1169-e1175.
781	6.	Rowe, P.C., et al., Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and
782		Management in Young People: A Primer. Frontiers in Pediatrics, 2017. 5(121).
783	7.	Rowe, K.S., Long Term Follow up of Young People With Chronic Fatigue Syndrome
784		Attending a Pediatric Outpatient Service. Frontiers in Pediatrics, 2019. 7(21).
785	8.	Crawley, E.M., A.M. Emond, and J.A. Sterne, Unidentified Chronic Fatigue
786		Syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school absence:
787	0	surveillance outcomes from school-based clinics. BMJ Open, 2011. 1(2): p. e000252.
788	9.	Similä, W.A., et al., <i>Health-related quality of life in Norwegian adolescents living with</i>
/89 700	10	chronic fatigue syndrome. Health and Quality of Life Outcomes, 2020. 18(1).
790 701	10.	Konna, M., et al., Impaired Health-Related Quality of Life in Adolescent Myalgic Encephalomyalitis/Chronic Eatigue Syndrome: The Impact of Core Symptoms, Eropt Pediatr
792		2019 7 n 26
793	11.	Kennedy, G., C. Underwood, and J.J.F. Belch. <i>Physical and Functional Impact of Chronic</i>
794		<i>Fatigue Syndrome/Myalgic Encephalomyelitis in Childhood.</i> Pediatrics, 2010. 125 (6): p.
795		e1324-e1330.
796	12.	Bakken, I.J., et al., Two age peaks in the incidence of chronic fatigue syndrome/myalgic
797		encephalomyelitis: a population-based registry study from Norway 2008-2012. BMC
798		Medicine, 2014. 12 (1).
799	13.	Jason, L.A., et al., <i>The Prevalence of Pediatric Myalgic Encephalomyelitis/Chronic Fatigue</i>
800		Syndrome in a Community Based Sample. Child Youth Care Forum, 2020. 49(4): p. 563-
801	14	5/9. Crewley F.M. A.M. Emond and I.A.C. Storme, Unidentified Chronic Estimate
802	14.	Syndrome/myalaic encephalomyalitis (CES/ME) is a major cause of school absence:
803 804		surveillance outcomes from school-based clinics BMI Open 2011 1(2): p e000252-
805		e000252.
806	15.	Josev, E.K., et al., <i>Health</i> , <i>Wellbeing</i> , and <i>Prognosis of Australian Adolescents with Myalgic</i>
807		Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Case-Controlled Follow-Up
808		Study. Journal of Clinical Medicine, 2021. 10(16): p. 3603.
809	16.	Sankey, A., et al., A follow-up study of chronic fatigue syndrome in children and adolescents:
810		symptom persistence and school absenteeism. Clin Child Psychol Psychiatry, 2006. 11(1): p.
811	. –	126-38.
812	17.	Bell, D.S., K. Jordan, and M. Robinson, <i>Thirteen-year follow-up of children and adolescents</i>
813		with chronic fatigue syndrome. Pediatrics, 2001. 107(5): p. 994-8.

- 18. Katz, B.Z. and L.A. Jason, *Chronic fatigue syndrome following infections in adolescents*.
 815 Curr Opin Pediatr, 2013. 25(1): p. 95-102.
- Hickie, I., et al., *Post-infective and chronic fatigue syndromes precipitated by viral and non- viral pathogens: prospective cohort study.* BMJ, 2006. 333(7568): p. 575.
- 818 20. Jason, L.A., et al., *Risks for Developing Myalgic Encephalomyelitis/Chronic Fatigue*819 Syndrome in College Students Following Infectious Mononucleosis: A Prospective Cohort
 820 Study. Clinical Infectious Diseases, 2021. **73**(11): p. e3740-e3746.
- 821 21. Choutka, J., et al., *Unexplained post-acute infection syndromes*. Nature Medicine, 2022.
 822 28(5): p. 911-923.
- Kedor, C., et al., A prospective observational study of post-COVID-19 chronic fatigue
 syndrome following the first pandemic wave in Germany and biomarkers associated with
 symptom severity. Nature Communications, 2022. 13(1): p. 5104.
- 826 23. Chu, L., et al., Onset Patterns and Course of Myalgic Encephalomyelitis/Chronic Fatigue
 827 Syndrome. Front Pediatr, 2019. 7: p. 12.
- Pedersen, M., et al., *Predictors of chronic fatigue in adolescents six months after acute Epstein-Barr virus infection: A prospective cohort study.* Brain, Behavior, and Immunity,
 2019. **75**: p. 94-100.
- 831 25. Moss-Morris, R., M.J. Spence, and R. Hou, *The pathway from glandular fever to chronic fatigue syndrome: can the cognitive behavioural model provide the map?* Psychological Medicine, 2011. **41**(5): p. 1099-1107.
- Katz, B.Z., et al., *Chronic Fatigue Syndrome After Infectious Mononucleosis in Adolescents*.
 Pediatrics, 2009. **124**(1): p. 189-193.
- 836 27. Gill, A.C., A. Dosen, and J.B. Ziegler, *Chronic Fatigue Syndrome in Adolescents: A Follow-*837 *up Study*. Archives of Pediatrics & Adolescent Medicine, 2004. **158**(3): p. 225-229.
- Candy, B., et al., *Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review.* Br J Gen Pract, 2002. **52**(483): p. 844-51.
- White, P.D., et al., *Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis.* The Lancet, 2001. **358**(9297): p. 1946-1954.
- Buchwald, D.S., et al., *Acute infectious mononucleosis: characteristics of patients who report failure to recover*. The American Journal of Medicine, 2000. **109**(7): p. 531-537.
- White, P.D., et al., *Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever.* The British Journal of Psychiatry, 1998. 173(6):
 p. 475-481.
- 847 32. Mirin, A.A., M.E. Dimmock, and L.A. Jason, *Updated ME/CFS prevalence estimates*848 *reflecting post-COVID increases and associated economic costs and funding implications.*849 Fatigue: Biomedicine, Health & amp; Behavior, 2022. 10(2): p. 83-93.
- 850 33. Komaroff, A.L. and L. Bateman, *Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?* Frontiers in Medicine, 2021. 7.
- 852 34. Roessler, M., et al., *Post-COVID-19-associated morbidity in children, adolescents, and*853 *adults: A matched cohort study including more than 157,000 individuals with COVID-19 in*854 *Germany.* PLOS Medicine, 2022. 19(11): p. e1004122.
- 855 35. Piraino, B., U. Vollmer-Conna, and A.R. Lloyd, *Genetic associations of fatigue and other*856 *symptom domains of the acute sickness response to infection*. Brain, Behavior, and Immunity,
 857 2012. 26(4): p. 552-558.
- 858 36. Wirth, K. and C. Scheibenbogen, A Unifying Hypothesis of the Pathophysiology of Myalgic
 859 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of
 860 autoantibodies against β2-adrenergic receptors. Autoimmun Rev, 2020. 19(6): p. 102527.
- 861 37. Renz-Polster, H., et al., *The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue*862 *Syndrome: The Case for Neuroglial Failure*. Front Cell Neurosci, 2022. 16: p. 888232.

863 38. Komaroff, A.L. and W.I. Lipkin, Insights from myalgic encephalomyelitis/chronic fatigue 864 syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol 865 Med, 2021. 27(9): p. 895-906. Cortes Rivera, M., et al., Mvalgic Encephalomvelitis/Chronic Fatigue Syndrome: A 866 39. 867 Comprehensive Review. Diagnostics, 2019. 9(3): p. 91. Rasa, S., et al., *Chronic viral infections in myalgic encephalomyelitis/chronic fatigue* 868 40. 869 syndrome (ME/CFS). J Transl Med, 2018. 16(1): p. 268. 870 41. Underhill, R.A., Myalgic encephalomyelitis, chronic fatigue syndrome: An infectious disease. 871 Medical Hypotheses, 2015. 85(6): p. 765-773. 872 42. Ruiz-Pablos, M., et al., Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front Immunol, 2021. 12: p. 656797. 873 874 43. Loebel, M., et al., Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic 875 Fatigue Syndrome. PLoS ONE, 2014. 9(1): p. e85387. Shikova, E., et al., *Cytomegalovirus*, *Epstein* \Box *Barr virus*, *and human herpesvirus* $\Box 6$ 876 44. 877 infections in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Journal of 878 Medical Virology, 2020. 92(12): p. 3682-3688. Komaroff, A.L., Chronic fatigue syndromes: relationship to chronic viral infections. J Virol 879 45. 880 Methods, 1988. **21**(1-4): p. 3-10. 881 46. Sepúlveda, N., et al., Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic 882 Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease 883 Diagnosis. Front Med (Lausanne), 2022. 9: p. 921101. 884 47. Pedersen, M., et al., Predictors of chronic fatigue in adolescents six months after acute 885 *Epstein-Barr virus infection: A prospective cohort study.* Brain Behav Immun, 2019. **75**: p. 886 94-100. 887 48. Nacul, L., et al., European Network on Myalgic Encephalomyelitis/Chronic Fatigue 888 Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care 889 of People with ME/CFS in Europe. Medicina (Kaunas), 2021. 57(5). 890 49. Clayton, E.W., Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report 891 on redefining an illness. JAMA, 2015. **313**(11): p. 1101-2. 892 Carruthers, B.M., et al., *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome*. Journal of 50. 893 Chronic Fatigue Syndrome, 2003. 11(1): p. 7-115. Jason, L.A., et al., A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic 894 51. 895 Fatigue Syndrome. Journal of Chronic Fatigue Syndrome, 2006. 13(2-3): p. 1-44. 896 Bateman, L., et al., Mvalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of 52. 897 Diagnosis and Management. Mayo Clin Proc, 2021. 96(11): p. 2861-2878. 898 53. Carmen Scheibenbogen, J.T.B.-S., Cornelia Heindrich, Kirsten Wittke, Elisa Stein, Christiana 899 Franke, Harald Prüss, Hannah Preßler, Marie-Luise Machule, Heinrich Audebert, Carsten 900 Finke, Hanna Gwendolyn Zimmermann, Birgit Sawitzki, Christian Meisel, Markus Tölle, Anne Krüger, Anna C. Aschenbrenner, Joachim L Schultze, Marc Daniel Beyer, Markus 901 902 Ralser, Michael Mülleder, Leif Erik Sander, Frank Konietschke, Friedemann Paul, Silvia 903 Stojanov, Lisa Bruckert, Dennis M Hedderich, Franziska Knolle, Gabriela Riemekasten, 904 Maria J.G.T. Vehreschild, Oliver A. Cornely, Uta Behrends, Susen Burock, Fighting Post-905 COVID and ME/CFS – development of curative therapies Frontiers in Medicine, in press. 906 Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Mil 54. 907 Med, 2015. 180(7): p. 721-3. 908 55. Moore, Y., et al., *Recovery from chronic fatigue syndrome: a systematic review*— 909 heterogeneity of definition limits study comparison. Archives of Disease in Childhood, 2021. 910 **106**(11): p. 1087-1094.

- 911 56. Norris, T., et al., *Natural course of chronic fatigue syndrome/myalgic encephalomyelitis in adolescents*. Archives of Disease in Childhood, 2017. **102**(6): p. 522-528.
- 58. Lim, A. and L. Lubitz, *Chronic fatigue syndrome: successful outcome of an intensive inpatient programme.* J Paediatr Child Health, 2002. 38(3): p. 295-9.
- 917 59. Rangel, L., et al., *The course of severe chronic fatigue syndrome in childhood*. Journal of the
 918 Royal Society of Medicine, 2000. 93(3): p. 129-134.
- 60. Krilov, L.R., et al., *Course and outcome of chronic fatigue in children and adolescents*.
 Pediatrics, 1998. **102**(2 Pt 1): p. 360-6.
- 921 61. Smith, M.S., et al., *Chronic fatigue in adolescents*. Pediatrics, 1991. **88**(2): p. 195-202.
- 922 62. Devendorf, A.R., et al., *Approaching recovery from myalgic encephalomyelitis and chronic* 923 *fatigue syndrome: Challenges to consider in research and practice.* Journal of Health
 924 Psychology, 2017. 24(10): p. 1412-1424.
- 63. Cairns, R. and M. Hotopf, A systematic review describing the prognosis of chronic fatigue
 syndrome. Occup Med (Lond), 2005. 55(1): p. 20-31.
- 64. Collin, S.M. and E. Crawley, Specialist treatment of chronic fatigue syndrome/ME: a cohort
 study among adult patients in England. BMC Health Serv Res, 2017. 17(1): p. 488.
- 65. Knight, S., et al., *Paediatric chronic fatigue syndrome: Complex presentations and protracted time to diagnosis.* Journal of Paediatrics and Child Health, 2013. 49(11): p. 919-924.
- 931 66. Solomon, L. and W.C. Reeves, *Factors influencing the diagnosis of chronic fatigue*932 *syndrome*. Arch Intern Med, 2004. 164(20): p. 2241-5.
- 933 67. Froehlich, L., et al., *Medical Care Situation of People with Myalgic*934 *Encephalomyelitis/Chronic Fatigue Syndrome in Germany*. Medicina, 2021. 57(7): p. 646.
- 935 68. Friedman, K.J., *Advances in ME/CFS: Past, Present, and Future*. Frontiers in Pediatrics, 2019. 7.
- 937 69. Sunnquist, M., et al., Access to Medical Care for Individuals with Myalgic Encephalomyelitis
 938 and Chronic Fatigue Syndrome: A Call for Centers of Excellence. Mod Clin Med Res, 2017.
 939 1(1): p. 28-35.
- 940 70. Varni, J.W., M. Seid, and P.S. Kurtin, *PedsQL 4.0: reliability and validity of the Pediatric*941 *Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.*942 Med Care, 2001. **39**(8): p. 800-12.
- 943 71. Morfeld, M., I. Kirchberger, and M. Bullinger, SF-36 Fragebogen zum Gesundheitszustand:
 944 Deutsche Version des Short Form-36 Health Survey. 2011.
- 945 72. Chalder, T., et al., *Development of a fatigue scale*. Journal of Psychosomatic Research, 1993.
 946 37(2): p. 147-153.
- 947 73. Wagner, D., et al., *Psychometric properties of the CDC Symptom Inventory for assessment of Chronic Fatigue Syndrome*. Population Health Metrics, 2005. **3**(1).
- 949 74. Bell, D.S., *The doctor's guide to chronic fatigue syndrome: Understanding, treating, and living with CFIDS.* 1995: Addison-Wesley Pub. Co.
- 951 75. R Core Team, *R: A Language and Environment for Statistical Computing*. 2023, R
 952 Foundation for Statistical Computing: Vienna, Austria.
- 953 76. Bakdash, J.Z. and L.R. Marusich, *Repeated Measures Correlation*. Frontiers in Psychology, 2017. 8.
- 77. Collin, S.M., et al., *Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) is*different in children compared to in adults: a study of UK and Dutch clinical cohorts. BMJ
 Open, 2015. 5(10): p. e008830.
- 958 78. Geraghty, K.J. and C. Adeniji, *The Importance of Accurate Diagnosis of ME/CFS in Children*959 *and Adolescents: A Commentary.* Frontiers in Pediatrics, 2019. 6.

960 79. Epstein-Barr-Virus: Von harmlos bis folgenschwer. 2017 [cited 2023 25.06.2023]; Available 961 from: https://www.gesundheitsforschung-bmbf.de/de/epstein-barr-virus-von-harmlos-bis-962 folgenschwer-7238.php. 963 80. Munich Long COVID Registry Study for Children, Adolescents and Adults (MLC-R). 964 Aufbau eines multizentrischen, altersübergreifenden, klinischen ME/CFS-Registers (MECFS-81. 965 R) sowie einer multizentrischen, altersübergreifenden ME/CFS-Biobank (MECFS-Bio) mit 966 Auswertung der epidemiologischen, klinischen Versorgungsdaten aus dem MECFS-R. 2022 967 [cited 2023 25.06.2023]; Available from: https://www.bundesgesundheitsministerium.de/ministerium/ressortforschung/handlungsfelder 968 969 /gesundheitsversorgung/mecfs.html. 970 Prevention, C.f.D.C.a. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. [cited 2023 82. 971 25.06.]; Available from: https://www.cdc.gov/me-cfs/healthcare-972 providers/diagnosis/index.html. 973 83. Webb, C.M., et al., What stops children with a chronic illness accessing health care: a mixed 974 methods study in children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis 975 (CFS/ME). BMC Health Serv Res, 2011. 11: p. 308. 976 84. Ghali, A., et al., Factors Influencing the Prognosis of Patients with Myalgic 977 Encephalomyelitis/Chronic Fatigue Syndrome. Diagnostics, 2022. 12: p. 2540. 978 White, P.H., et al., Supporting the Health Care Transition From Adolescence to Adulthood in 85. 979 the Medical Home. Pediatrics, 2018. 142(5): p. e20182587. 980 Loades, M.E., E.A. Sheils, and E. Crawley, *Treatment for paediatric chronic fatigue* 86. 981 syndrome or myalgic encephalomyelitis (CFS/ME) and comorbid depression: a systematic 982 review. BMJ Open, 2016. 6(10): p. e012271. 983 87. Loades, M.E., et al., How common are depression and anxiety in adolescents with chronic 984 fatigue syndrome (CFS) and how should we screen for these mental health co-morbidities? A 985 clinical cohort study. Eur Child Adolesc Psychiatry, 2021. **30**(11): p. 1733-1743. 986 88. Castro-Marrero, J., et al., *Comorbidity in Chronic Fatigue Syndrome/Myalgic* 987 Encephalomyelitis: A Nationwide Population-Based Cohort Study. Psychosomatics, 2017. 988 **58**(5): p. 533-543. 989 89. Stewart, J.M., et al., Orthostatic intolerance in adolescent chronic fatigue syndrome. 990 Pediatrics, 1999. 103(1): p. 116-21. 991 90. Freeman, R., et al., Consensus statement on the definition of orthostatic hypotension, neurally 992 mediated syncope and the postural tachycardia syndrome. Clin Auton Res, 2011. 21(2): p. 993 69-72. 994 91. Katz, B.Z., et al., Orthostatic tolerance testing in a prospective cohort of adolescents with 995 chronic fatigue syndrome and recovered controls following infectious mononucleosis. Clin 996 Pediatr (Phila), 2012. 51(9): p. 835-9. 997 92. Porter, N.S., et al., Alternative medical interventions used in the treatment and management 998 of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J Altern 999 Complement Med, 2010. 16(3): p. 235-49. 1000 93. Parslow, R., et al., What matters to children with CFS/ME? A conceptual model as the first 1001 *stage in developing a PROM.* Arch Dis Child, 2015. **100**(12): p. 1141-7. 1002 94. Knight, S.J., et al., School Functioning in Adolescents With Chronic Fatigue Syndrome. 1003 Frontiers in Pediatrics, 2018. 6. 1004 Repka-Ramirez, M.S., et al., IgE levels are the same in chronic fatigue syndrome (CFS) and 95. 1005 control subjects when stratified by allergy skin test results and rhinitis types. Ann Allergy 1006 Asthma Immunol, 2001. 87(3): p. 218-21. 1007 96. Earl, K.E., et al., Vitamin D status in chronic fatigue syndrome/myalgic encephalomyelitis: a 1008 cohort study from the North-West of England. BMJ Open, 2017. 7(11): p. e015296.

97.	De Paschale, M., et al., Seroepidemiology of EBV and interpretation of the "isolated VCA Informattern I Med Virol 2009 81(2): p. 325-31
98	Niller H -H and G Bauer Enstein-Barr Virus: Clinical Diagnostics in Enstein Barr Virus:
<i>J</i> 0.	Mathods and Protocols I Minarovits and H H Niller Editors 2017 Springer New York:
	New York NV p 23.55
00	New TOIR, N.I. p. 55-55. Ikuta K at al. Detection of Enstein Barr virus in salivas and throat washings in healthy
<i>уу</i> .	adults and children Microbes Infect 2000 2(2): p. 115-20
100	Hogue T and D H Crowford PCP amplification is more sensitive than tissue culture
100.	matheds for Enstein Barr virus detection in aliniaal material Journal of Conoral Virology
	1007 78 (12): p 3357-3360
101	Kanakry I Δ et al. The clinical significance of FRV DNA in the plasma and peripheral
101.	blood mononuclear cells of patients with or without FRV diseases Blood 2016 127 (16): p
	2007_17
102	P asa S et al. Chronic viral infactions in myalaic ancaphalomyalitis/chronic fatigue
102.	syndrome (ME/CES) Journal of Translational Medicine 2018 16 (1)
103	Let ΔM et al. I a M serum antibodies to Enstein-Barr virus are uniquely present in a
105.	subset of patients with the chronic fatigue syndrome. In Vivo 2004 18(2): p. 101-6
104	Subset of patients with the chronic fulgue synarome. In VIVO, 2004. 10(2). p. 101-0.
104.	harnesvirus 7 in patients with chronic fatigue syndrome. Intervirology 1005 38(5): p. 260-
	73
105	I.e. I.S. et al. Salivary DNA Loads for Human Herpesviruses 6 and 7 Are Correlated With
105.	Disease Phenotype in Myalaic Encephalomyalitis/Chronic Fatigue Syndrome Front Med
	(Lausanne) 2021 8 n 656602
106	(Lausanne), 2021. 6. p. 050072.
100.	of Chronic Fatigue Syndrome/Myalaic Encenhalomyalitis Front Pediatr 2010 7: p 50
107	Loebel M et al. Secological profiling of the ERV immune response in Chronic Fatigue
107.	Syndrome using a pentide microarray PLoS One 2017 12(6): p. e0179124
108	Statistics Of n Prevalence of ongoing symptoms following coronavirus (COVID-10)
100.	infaction in the IIK 2023 30.03 [cited 2023 25.06]: Available from:
	https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddi
	seases/hulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/
	30march2023
109	Cairns R and M Hotopf A systematic review describing the prognosis of chronic fatigue
107.	syndrome Occupational Medicine 2005 55(1): p 20-31
110	Devendorf A R et al Approaching recovery from myalgic encephalomyelitis and chronic
1101	fatigue syndrome: Challenges to consider in research and practice. Journal of Health
	Psychology, 2019. 24 (10): p. 1412-1424.
111.	Ison L.A. et al. Predictors of post-infectious chronic fatigue syndrome in adolescents
	Health Psychology and Behavioral Medicine, 2014, 2 (1): p. 41-51.
112	Lievesley, K. K.A. Rimes and T. Chalder. A review of the predisposing precipitating and
	perpetuating factors in Chronic Fatigue Syndrome in children and adolescents. Clin Psychol
	Rev. 2014. 34 (3): p. 233-48.
113.	Rimes, K.A., et al., Incidence, prognosis, and risk factors for fatigue and chronic fatigue
	syndrome in adolescents: a prospective community study. Pediatrics, 2007, 119 (3): p. e603-9.
114.	Rangel, L., et al., The course of severe chronic fatigue syndrome in childhood. J.R. Soc Med.
	2000. 93 (3): p. 129-34.
115.	Jason, L.A. and M. Sunnquist, The Development of the DePaul Symptom Questionnaire:
-	Original, Expanded, Brief, and Pediatric Versions. Frontiers in pediatrics, 2018. 6: p. 330-
	330.
	 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115.

- 1058 116. Knight, S.J., et al., Measuring quality of life and fatigue in adolescents with chronic fatigue
 1059 syndrome: estimates of feasibility, internal consistency and parent–adolescent agreement of
 1060 the PedsQLTM. Fatigue: Biomedicine, Health & Behavior, 2015. 3(4): p. 220-234.
- 1061 117. Winger, A., et al., *Health related quality of life in adolescents with chronic fatigue syndrome:* 1062 *a cross-sectional study*. Health and Quality of Life Outcomes, 2015. 13(1): p. 96.
- 1063 118. Varni, J.W., et al., *The PedsQL 4.0 as a pediatric population health measure: feasibility,* 1064 *reliability, and validity.* Ambul Pediatr, 2003. **3**(6): p. 329-41.
- 1065 119. Falk Hvidberg, M., et al., *The Health-Related Quality of Life for Patients with Myalgic*1066 *Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)*. PLoS One, 2015. 10(7): p.
 1067 e0132421.
- 1068 120. Eaton-Fitch, N., et al., *Health-related quality of life in patients with myalgic* 1069 *encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study.* Qual Life
 1070 Res, 2020. 29(6): p. 1521-1531.
- 1071 121. Similä, W.A., et al., *Health-related quality of life in Norwegian adolescents living with* 1072 *chronic fatigue syndrome.* Health Qual Life Outcomes, 2020. **18**(1): p. 170.
- 1073 122. Borch, L., et al., *Long COVID symptoms and duration in SARS-CoV-2 positive children a* 1074 *nationwide cohort study.* Eur J Pediatr, 2022. **181**(4): p. 1597-1607.
- 1075

1076 **5 Figure Legends**

1077

Figure 1. Alluvial chart illustrating ME/CFS diagnostic criteria fulfillment over the study period for adults and adolescents.

The chart depicts diagnostic criteria fulfillment (red) or non-fullfillment (green) at the first visit and at visits 6 and 12 months later. (Non-)fullfillment of Canadian Consensus Criteria (CCC) is shown for adults. (Non)-fullfillment of CCC only, Rowe's diagnostic worksheet (CDW-R) criteria only, or either of both (CCC or CDW-R) is shown for adolescents. CDW-R criteria were not applicable anymore (N/A) when adolescent patients had turned 18 years. Overall, the chart provides an overview of the changes in diagnostic status for ME/CFS patients over time.

1086

Figure 2. Frequency and severity of symptoms at diagnosis (first visit) and at visits six and twelf months later

The bar-chart displays individual symptoms on the x-axis, while the y-axis shows the frequency of symptoms on the left and the severity of symptoms on the right. The severity scale for each individual symptom ranged from 0 (not present) to 4 (severe), and the frequency scale from 0 (not present) to 5 (always present). At each time point, the chart shows the proportion of patients reporting each symptom with respective severity and frequency rating, indicated by color-code.

1094 The chart provides an overview of the most common symptoms in ME/CFS patients, how 1095 frequently they occured, and how severe they were. It also illustrates how the frequency and severity 1096 of symptoms changed over time, with some symptoms improving or worsening and others remaining 1097 consistent.

1098

Figure 3. Patient reported outcome measures at diagnosis (first visit) and at visits six and twelf months later

Boxplots displaying the dynamics of results from the Chalder Fatigue Scale (A), the Bell Score (B), the SF-36 physical (C) and mental health component summary score (D), and the Pediatric Quality of Life Inventory (E) for the entire cohort as well as for adolescents and adults only, respectively.

1105

1106 Figure 4. Correlation of patient reported outcomes

- 1107 Heatmap of repeated measures correlations between patient reported outcomes for all patients (A),
- 1108 adults only (B), and adolescents only (C). Repeated measures correlations are a statistical tool to
- 1109 determine the overall within-patient correlation between a pair of variables.

1111 6 Tables

1112 Table 1. Baseline Demographics and Clinical Characteristics of the Cohort

Characteristics	All	Adults	Adolescents	p-value ¹	
Number of patients	n=25	n=13	n=12		
Age and illness duration ²					
Age at first visit	18 (16 – 21)	21 (19 – 22)	16(14–16)	< 0.001	
Age at onset	16 (14 – 19)	19 (18 – 21)	15 (13 – 15)	< 0.001	
Illness duration in months from onset to first visit	13.8 (9.1 – 34.9)	16.9 (9.4 – 44.1)	13.2 (8.8 – 22.0)	0.503	
Baseline questionnaire results					
Chalder fatigue scale ³	25 (5)	28 (4)	22 (5)	0.006	
Bell Score ²	40 (30 - 50)	30 (30 – 40)	50 (40-50)	0.056	
SF-36 PCS ³	29 (9)	26 (8)	32 (9)	0.151	
SF-36 MCS ³	42 (11)	39 (12)	45 (9)	0.211	
PedsQL ³	46 (14)	35 (11)	54 (9)	0.002	
Gender ⁴					
Female	20/25 (80)	11/13 (85)	9/12 (75)	0.645	
ME/CFS criteria ⁴					
CCC	21/25 (84)	13/13 (100)	8/12 (67)	0.039	
CDW-R	12/12 (100)	N/A	12/12 (100)	0.077	
Comorbidity ⁴					
PoTS	19/23 (83)	11/11 (100)	8/10 (80)	>0.999	
Allergies	12/25 (48)	7/13 (54)	5/12 (42)	0.543	
Asthma	1/25 (4)	0/13 (0)	1/12 (8)	>0.999	
Neurodermatitis	1/25 (4)	1/13 (8)	0/12(0)	>0 999	
Psychiatric disorder	3/25(12)	2/13 (15)	$\frac{1}{12}(0)$	>0.999	
Medical history ⁴				, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Trauma/surgery	1/25 (4)	0/13 (0)	1/12 (8)	0.480	
Asthma	2/25(8)	1/13 (8)	1/12(8)	>0.999	
Psychiatric disorder	1/25 (4)	0/13 (0)	1/12 (8)	0.480	
Current medical care ⁴					
Complete vaccinations	22/22 (100)	11/11 (100)	11/11 (100)		
Nutrition supplements	17/24 (71)	10/12 (83)	7/12 (58)	0.319	
Prescription medication	11/24 (46)	5/12 (42)	6/12 (50)	>0.999	
Degree of disability	1/25 (4)	0/13 (0)	1/12 (8)	>0.999	
Medical aid	0/25 (0)	0/13 (0)	0/12 (0)		
Long-term care level	0/25 (0)	0/13 (0)	0/12 (0)		
Family history ⁴					
ME/ CFS in family	2/25 (8)	1/13 (8)	1/12 (8)	>0.999	
AID in family	10/25 (40)	6/13 (46)	4/12 (33)	0.688	
PID in family	0/25 (0)	0/13 (0)	0/12 (0)		
IM in family	16/25 (64)	9/13 (69)	7/12 (58)	0.688	

¹Fisher's exact test; Wilcoxon rank sum test; Pearson's Chi-squared test

² Median (IQR)

³ Mean (SD)

⁴ Number of patients with indicated characteristic/number of patients investigated (%)

CCC, Canadian Consensus Criteria [49], CDW-R, Clinical Diagnostic Worksheet [6]; PoTS, postural orthostatic tachycardia syndrome; AID, autoimmune disease; PID, primary immune deficiency; IM, infectious mononucleosis; PedsQL, Pediatric Quality of Life Inventory; SF-36 PCS, Short Form 36 Health Survey Physical Component Summary Score; SF-36 MCS, Short Form 36 Health Survey Mental Health Component Summary Score. N/A, not applicable.

Table 2. Selected Laboratory Results at Baseline Visit

Laboratory parameter	All $n/n (\%)^1$	Adults $n/n (\%)^1$	Adolescents n/n (%) ¹	p-value ²					
Blood count									
Neutropenia (<1,500/ul)	2/25 (8)	1/13 (8)	1/12 (8)	>0.999					
Lymphocytes ↑	5/25 (20)	2/13 (15)	3/12 (25)	0.645					
Thrombocytes \downarrow	0/25 (0)	0/13 (0)	0/12 (0)						
Hemoglobin ↓	4/25 (16)	1/13 (8)	3/12 (25)	0.322					
Inflammation									
Sedimentation rate \uparrow	1/21 (5)	0/13 (0)	1/8 (12.5)	0.350					
C-reactive protein ↑	0/25 (0)	0/13 (0)	0/12 (0)						
Ferritin ↑	2/23 (9)	0/13 (0)	2/10 (20)	0.178					
Liver function									
GOT ↑	1/25 (4)	0/13 (0)	1/12 (8)	0.480					
GPT ↑	2/25 (8)	0/13 (0)	2/12 (17)	0.220					
Bilirubin ↑	1/24 (4)	1/13 (8)	0/11 (0)	>0.999					
Immunoglobulins (Ig)									
IgA ↓↑	0/25 (0)	0/13 (0)	0/12 (0)						
IgM ↓↑	0/25 (0)	0/13 (0)	0/12 (0)						
IgG ↓↑	0/25 (0)	0/13 (0)	0/12 (0)						
IgE↑	7/25 (28)	3/13 (23)	4/12 (33)	0.673					
Infection Serology									
Cytomegalovirus IgG	3/25 (12)	2/13 (15)	1/12 (8)	>0.999					
Herpes simplex virus IgG	3/25 (12)	2/13 (15)	1/12 (8)	>0.999					
Toxoplasma IgG	1/25 (4)	1/13 (78)	0/12 (0)	>0.999					
Borrelia IgG	1/25 (4)	0/13 (0)	1/12 (8)	0.480					
Autoantibodies									
ANA ↑	14/25 (56)	8/13 (62)	6/12 (50)	0.561					
ANCA ↑	1/25 (4)	1/13 (8)	0/12 (0)	>0.999					
Anti-dsDNA ↑	0/25 (0)	0/13 (0)	0/12 (0)						
Endocrinology									
Cortisol ↓	1/25 (4)	1/13 (18)	0/12 (0)	0.480					
ACTH ↑	1/23 (4)	0/12 (0)	1/11 (9)	0.478					
25-OH-Vitamin-D↓	14/24 (58)	6/12 (50)	8/12 (67)	0.680					

¹Number of patients with indicated laboratory parameter/ number of patients investigated (%)

² Fisher's exact test; Pearson's Chi-squared test

↑ above normal range; ↓ below normal range; ANA, antinuclear antibodies; ANCA, anti-cytoplasmatic antibodies; anti-dsDNA, anti-double strand DNA

1125 **Table 3**: EBV Serology, PCR and IgG Immunoblot at Baseline Visit

EBV Diagnostics	All $n/n (\%)^1$	Adults $n/n (\%)^1$	Adolescents n/n (%) ¹	p-value ²
EBV PCR				
DNA in cell fraction				0.927
- (+) +	12/20 (60) 5/20 (25) 3/20 (15)	7/12 (58) 3/12 (25) 2/12 (17)	5/8 (62) 2/8 (25) 1/8 (12)	
DNA in plasma	5/20 (15)	2/12(17)	1/0 (12)	
_	25/25 (100)	13/13 (100)	12/12 (100)	
+	0/25 (0)	0/12 (0)	0/12 (0)	0.000
DNA in throat wash	11/25 (44)	6/12 (16)	5/12 (42)	>0.999
+	14/25 (66)	7/13 (54)	5/12 (42) 7/12 (54)	
EBV ELISA	1 1/20 (00)	() 10 (0 l)	(12(01)	
VCA IgM				0.110
-	18/25 (72)	7/13 (54)	11/12 (92)	
(+)	1/25 (4)	1/13 (8)	0/12 (0)	
	6/25 (24)	5/13 (38)	1/12 (8)	
	0/25(0)	0/13(0)	0/12(0)	
+	25/25 (100)	13/13 (100)	12/12 (100)	
EBNA1 IgG				0.220
_	2/25 (8)	0/13 (0)	2/12 (17)	
+	23/25 (92)	13/13 (100)	10/12 (83)	
EBV IgG Immunobiot				0.282
	14/25 (56)	7/13 (54)	7/12 (58)	0.282
(+)	3/25 (12)	3/13 (23)	0/12 (0)	
+	8/25 (32)	3/13 (23)	5/12 (42)	
EAp138				0.233
	14/25 (56)	6/13 (46)	8/12 (67)	
(+)	6/23 (24) 5/25 (20)	2/13 (38)	$\frac{1}{12}(8)$ $\frac{3}{12}(25)$	
BZLF1	5/25 (20)	2/13 (13)	5/12 (25)	0.293
_	3/25 (12)	3/13 (23)	0/12 (0)	
(+)	4/25 (16)	2/13 (15)	2/12 (17)	
+	18/25 (72)	8/13 (62)	10/12 (83)	> 0.000
	2/25 (8)	1/13 (8)	1/12 (8)	>0.999
(+)	0/25 (0)	0/13(0)	0/12(0)	
+	23/25 (92)	12/13 (92)	11/12 (92)	
VCAp18				0.480
	1/25 (4)	0/13 (0)	1/12 (8)	
(+)	0/25 (0)	0/13(0) 13/13(100)	0/12(0) 11/12(92)	
EBNA-1	2 4 /23 (70)	15/15 (100)	11/12 (72)	0.344
_	2/25 (8)	0/13 (0)	2/12 (17)	0.011
(+)	1/25 (4)	1/13 (8)	0/12 (0)	
+	22/25 (88)	12/13 (92)	10/12 (83)	

¹ Number of patients with indicated laboratory parameter/ number of patients investigated (%) ² Fisher's exact test

EBV, Epstein-Barr Virus; VCA, virus capsid antigen; EBNA, EBV nuclear antigen; EA, early antigen.

	All (n=25)				Adults (n=13)				Adolescents (n=12)			
	First Visit	6 Months	12 Months	p-value ¹	First Visit	6 Months	12 Months	p-value ¹	First Visit	6 Months	12 Months	p-value ¹
Bell Score ²	40 (30, 50)	40 (30, 63)	40 (30, 60)	0.384	30 (30, 40)	30 (30, 40)	30 (25, 35)	0.368	50 (40, 50)	60 (40, 80)	60 (40, 80)	0.232
PedsQL ³												
Total Score	46 (14)	50 (19)	50 (21)	0.718	35 (11)	37 (15)	37 (15)	0.968	54 (9)	62 (14)	61 (20)	0.368
Physical	40 (18)	46 (24)	40 (26)	0.748	30 (12)	29 (13)	25 (15)	0.842	48 (18)	60 (22)	53 (27)	0.531
Psychosocial	49 (14)	53 (18)	56 (20)	0.698	38 (13)	41 (17)	45 (19)	0.695	58 (6)	63 (14)	64 (18)	0.719
School	33 (14)	43 (22)	47 (28)	0.115	29 (18)	37 (22)	33 (26)	0.871	35 (11)	48 (23)	58 (25)	0.030
Social	66 (21)	64 (20)	64 (20)	0.919	50 (18)	49 (15)	51 (15)	0.916	77 (16)	76 (16)	76 (16)	0.944
Emotional	50 (21)	49 (24)	53 (25)	0.843	34 (15)	36 (23)	44 (21)	0.357	61 (17)	60 (19)	60 (27)	0.921
SF-36 ³												
Physical functioning	54 (25)	60 (26)	55 (34)	0.792	42 (21)	46 (20)	35 (27)	0.806	65 (25)	71 (25)	73 (31)	0.581
Role physical	12 (15)	18 (33)	22 (37)	0.897	7 (12)	3 (8)	6(11)	0.677	17 (16)	30 (40)	38 (46)	0.843
Bodily pain	41 (26)	49 (27)	49 (29)	0.433	34 (21)	34 (15)	37 (23)	0.929	47 (29)	62 (29)	60 (31)	0.335
General health	26 (12)	28 (15)	29 (17)	0.865	22 (11)	21 (9)	20 (7)	0.969	30 (12)	35 (15)	37 (20)	0.685
Vitality	22 (14)	29 (22)	27 (26)	0.737	15 (13)	18 (11)	11 (8)	0.481	29 (12)	38 (24)	42 (28)	0.447
Social functioning	41 (27)	43 (33)	41 (35)	0.980	31 (23)	24 (22)	24 (25)	0.520	51 (27)	59 (32)	58 (36)	0.636
Role emotional	71 (39)	55 (41)	65 (44)	0.444	64 (46)	52 (44)	56 (47)	0.824	78 (33)	58 (40)	73 (41)	0.383
Mental health	59 (19)	54 (22)	59 (21)	0.756	52 (20)	43 (20)	51 (18)	0.471	65 (17)	63 (19)	66 (21)	0.923
Physical component summary score	29 (9)	34 (12)	32 (13)	0.434	26 (8)	28 (8)	25 (9)	0.839	32 (9)	38 (13)	38 (13)	0.302
Mental health component summary score	42 (11)	39 (13)	41 (12)	0.589	39 (12)	34 (11)	37 (11)	0.631	45 (9)	42 (14)	45 (12)	0.817

1127 Table 4. Patient-reported Outcome Measures of the Cohort

¹ Kruskal-Wallis rank sum test.

² Median (IQR) ³ Mean (SD)

PedsQL, Pediatric Quality of Life Inventory; SF-36, Short Form 36 Health Survey.











6Months

12 Months

B) CCC – Adolescents

2 -

0

First Visit

Figure 2 A) Frequency of Symptoms



B) Severity of Symptoms



Figure 3



Figure 4

